Page last updated: 2024-10-22

ambroxol and Idiopathic Parkinson Disease

ambroxol has been researched along with Idiopathic Parkinson Disease in 16 studies

Ambroxol: A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.

Research Excerpts

ExcerptRelevanceReference
"The ambroxol therapy was well tolerated, with no serious adverse events."6.94Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial. ( Cable, S; Campbell, P; D'Souza, G; Elflein, J; Foltynie, T; Hällqvist, J; Hehir, J; Heywood, WE; Hosking, J; Khengar, R; Lee, K; Libri, V; Limousin, P; Mills, K; Mullin, S; Schapira, AHV; Smith, L; Streeter, A; Toffoli, M; Woodgate, P; Zetterberg, H, 2020)
"Ambroxol is a pharmacological chaperone for GCase and is able to raise the levels of GCase and could therefore be a disease-modifying treatment for PDD."6.90Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. ( Bartha, R; Borrie, M; Coleman, K; Finger, E; Hegele, RA; Jenkins, ME; Jog, M; Li, Z; MacDonald, P; MacKinley, J; Mahuran, D; Morrow, SA; Pasternak, SH; Rupar, CA; Silveira, CRA; Tirona, RG; Wells, J; Zou, G, 2019)
"Both patients with non-neuronopathic Gaucher disease (GD) and heterozygous GBA mutation carrier are at increased risk for Parkinson disease (PD)."6.58Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development. ( Arkadir, D; Dinur, T; Ilan, Y; Ishay, Y; Szer, J; Zimran, A, 2018)
"Ambroxol hydrochloride is an oral mucolytic drug available over-the-counter for many years as cough medicine."5.62Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data. ( Al-Hertani, W; Becker-Cohen, M; Castillo-Garcia, D; Ceron-Rodriguez, M; Chan, A; Dinur, T; Fiumara, A; Istaiti, M; Kiec-Wilk, B; Lee, BH; Ramaswami, U; Revel-Vilk, S; Rodic, P; Rubio, B; Tincheva, RS; Yang, CF; Zimran, A, 2021)
"Ambroxol treatment significantly reduced HexSph concentration in GD (by 2."5.62Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism. ( Baydakova, GV; Bezrukikh, VA; Bogdanova, DA; Bolshakova, OI; Cheblokov, AA; Emelyanov, AK; Kopytova, AE; Miliukhina, IV; Nikolaev, MA; Pchelina, SN; Rychkov, GN; Salogub, GN; Sarantseva, SV; Senkevich, KA; Usenko, TC; Zakharova, EY, 2021)
"Treatment with ambroxol hydrochloride increased glucosylceramidase activity in fibroblasts from healthy controls, Gaucher disease and heterozygous glucocerebrosidase mutation carriers with and without Parkinson's disease."5.40Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. ( Abramov, AY; Chau, KY; Cooper, JM; Foltynie, T; Gegg, M; Hughes, D; Magalhaes, J; McNeill, A; Mehta, A; Schapira, AH; Shen, C, 2014)
" The literature review of the usage of ambroxol acting as a pharmacological chaperone for beta-glucocerebrosidase in Gaucher disease and Parkinson’s disease associated with GBA variants has been reviewed."5.22Pharmacological chaperone therapy for the treatment of inborn errors of metabolism ( Jezela-Stanek, A; Lipiński, P; Tylki-Szymańska, A, 2022)
"Our work supports the proposition that ambroxol should be further investigated as a potential novel disease-modifying therapy for treatment of Parkinson disease and neuronopathic Gaucher disease to increase glucocerebrosidase activity and decrease α-synuclein and phosphorylated α-synuclein protein levels."3.83Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice. ( Bezard, E; Daly, L; Migdalska-Richards, A; Schapira, AH, 2016)
"The ambroxol therapy was well tolerated, with no serious adverse events."2.94Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial. ( Cable, S; Campbell, P; D'Souza, G; Elflein, J; Foltynie, T; Hällqvist, J; Hehir, J; Heywood, WE; Hosking, J; Khengar, R; Lee, K; Libri, V; Limousin, P; Mills, K; Mullin, S; Schapira, AHV; Smith, L; Streeter, A; Toffoli, M; Woodgate, P; Zetterberg, H, 2020)
"Ambroxol is a pharmacological chaperone for GCase and is able to raise the levels of GCase and could therefore be a disease-modifying treatment for PDD."2.90Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. ( Bartha, R; Borrie, M; Coleman, K; Finger, E; Hegele, RA; Jenkins, ME; Jog, M; Li, Z; MacDonald, P; MacKinley, J; Mahuran, D; Morrow, SA; Pasternak, SH; Rupar, CA; Silveira, CRA; Tirona, RG; Wells, J; Zou, G, 2019)
"Both patients with non-neuronopathic Gaucher disease (GD) and heterozygous GBA mutation carrier are at increased risk for Parkinson disease (PD)."2.58Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development. ( Arkadir, D; Dinur, T; Ilan, Y; Ishay, Y; Szer, J; Zimran, A, 2018)
"Ambroxol hydrochloride is an oral mucolytic drug available over-the-counter for many years as cough medicine."1.62Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data. ( Al-Hertani, W; Becker-Cohen, M; Castillo-Garcia, D; Ceron-Rodriguez, M; Chan, A; Dinur, T; Fiumara, A; Istaiti, M; Kiec-Wilk, B; Lee, BH; Ramaswami, U; Revel-Vilk, S; Rodic, P; Rubio, B; Tincheva, RS; Yang, CF; Zimran, A, 2021)
"Ambroxol treatment significantly reduced HexSph concentration in GD (by 2."1.62Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism. ( Baydakova, GV; Bezrukikh, VA; Bogdanova, DA; Bolshakova, OI; Cheblokov, AA; Emelyanov, AK; Kopytova, AE; Miliukhina, IV; Nikolaev, MA; Pchelina, SN; Rychkov, GN; Salogub, GN; Sarantseva, SV; Senkevich, KA; Usenko, TC; Zakharova, EY, 2021)
"Treatment with ambroxol hydrochloride increased glucosylceramidase activity in fibroblasts from healthy controls, Gaucher disease and heterozygous glucocerebrosidase mutation carriers with and without Parkinson's disease."1.40Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. ( Abramov, AY; Chau, KY; Cooper, JM; Foltynie, T; Gegg, M; Hughes, D; Magalhaes, J; McNeill, A; Mehta, A; Schapira, AH; Shen, C, 2014)

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's9 (56.25)24.3611
2020's7 (43.75)2.80

Authors

AuthorsStudies
Yang, SY2
Taanman, JW2
Gegg, M2
Schapira, AHV3
Tripathi, P1
Ganeshpurkar, A1
Singh, SK1
Krishnamurthy, S1
Lipiński, P1
Jezela-Stanek, A1
Tylki-Szymańska, A1
Mullin, S1
Smith, L1
Lee, K1
D'Souza, G1
Woodgate, P1
Elflein, J1
Hällqvist, J1
Toffoli, M1
Streeter, A1
Hosking, J1
Heywood, WE1
Khengar, R1
Campbell, P1
Hehir, J1
Cable, S1
Mills, K1
Zetterberg, H1
Limousin, P1
Libri, V1
Foltynie, T2
Schneider, SA1
Alcalay, RN1
Istaiti, M1
Revel-Vilk, S1
Becker-Cohen, M1
Dinur, T2
Ramaswami, U1
Castillo-Garcia, D1
Ceron-Rodriguez, M1
Chan, A1
Rodic, P1
Tincheva, RS1
Al-Hertani, W1
Lee, BH1
Yang, CF1
Kiec-Wilk, B1
Fiumara, A1
Rubio, B1
Zimran, A2
Kopytova, AE1
Rychkov, GN1
Nikolaev, MA1
Baydakova, GV1
Cheblokov, AA1
Senkevich, KA1
Bogdanova, DA1
Bolshakova, OI1
Miliukhina, IV1
Bezrukikh, VA1
Salogub, GN1
Sarantseva, SV1
Usenko, TC1
Zakharova, EY1
Emelyanov, AK1
Pchelina, SN1
Silveira, CRA1
MacKinley, J1
Coleman, K1
Li, Z1
Finger, E1
Bartha, R1
Morrow, SA1
Wells, J1
Borrie, M1
Tirona, RG1
Rupar, CA1
Zou, G1
Hegele, RA1
Mahuran, D1
MacDonald, P1
Jenkins, ME1
Jog, M1
Pasternak, SH1
McNeill, A1
Magalhaes, J1
Shen, C1
Chau, KY3
Hughes, D1
Mehta, A1
Cooper, JM1
Abramov, AY1
Schapira, AH3
Albin, RL1
Dauer, WT1
Ambrosi, G1
Ghezzi, C1
Zangaglia, R1
Levandis, G1
Pacchetti, C1
Blandini, F1
Maor, G1
Cabasso, O1
Krivoruk, O1
Rodriguez, J1
Steller, H1
Segal, D1
Horowitz, M1
Sanchez-Martinez, A1
Beavan, M2
Gegg, ME1
Whitworth, AJ1
Migdalska-Richards, A1
Daly, L1
Bezard, E1
Ishay, Y1
Szer, J1
Ilan, Y1
Arkadir, D1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients With Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease[NCT02941822]Phase 223 participants (Actual)Interventional2016-12-31Completed
Ambroxol as a Disease-modifying Treatment to Reduce the Risk of Cognitive Impairment in GBA-associated Parkinson's Disease. A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Trial[NCT05287503]Phase 265 participants (Actual)Interventional2022-02-15Active, not recruiting
Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia[NCT04405596]Phase 1/Phase 215 participants (Anticipated)Interventional2025-01-31Not yet recruiting
Effect of Ambroxol on the Inflammatory Markers and Clinical Outcome of Patients With Diabetic Peripheral Neuropathy[NCT05558878]80 participants (Anticipated)Interventional2022-10-01Not yet recruiting
Ambroxol as a Novel Disease Modifying Treatment for Parkinson's Disease Dementia[NCT02914366]Phase 255 participants (Actual)Interventional2015-11-30Active, not recruiting
Genotypic Influences on Network Progression in Parkinson's Disease[NCT04228172]32 participants (Anticipated)Observational2020-02-24Recruiting
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy[NCT03950050]Phase 240 participants (Actual)Interventional2019-03-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

2 reviews available for ambroxol and Idiopathic Parkinson Disease

ArticleYear
Pharmacological chaperone therapy for the treatment of inborn errors of metabolism
    Postepy biochemii, 2022, 09-30, Volume: 68, Issue:3

    Topics: Ambroxol; Gaucher Disease; Humans; Mutation; Parkinson Disease

2022
Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development.
    Blood cells, molecules & diseases, 2018, Volume: 68

    Topics: Ambroxol; Animals; Anti-Inflammatory Agents; Drug Discovery; Expectorants; Gaucher Disease; Glucosyl

2018

Trials

2 trials available for ambroxol and Idiopathic Parkinson Disease

ArticleYear
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
    JAMA neurology, 2020, 04-01, Volume: 77, Issue:4

    Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen

2020
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
    JAMA neurology, 2020, 04-01, Volume: 77, Issue:4

    Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen

2020
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
    JAMA neurology, 2020, 04-01, Volume: 77, Issue:4

    Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen

2020
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
    JAMA neurology, 2020, 04-01, Volume: 77, Issue:4

    Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen

2020
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
    JAMA neurology, 2020, 04-01, Volume: 77, Issue:4

    Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen

2020
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
    JAMA neurology, 2020, 04-01, Volume: 77, Issue:4

    Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen

2020
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
    JAMA neurology, 2020, 04-01, Volume: 77, Issue:4

    Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen

2020
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
    JAMA neurology, 2020, 04-01, Volume: 77, Issue:4

    Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen

2020
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
    JAMA neurology, 2020, 04-01, Volume: 77, Issue:4

    Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen

2020
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
    JAMA neurology, 2020, 04-01, Volume: 77, Issue:4

    Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen

2020
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
    JAMA neurology, 2020, 04-01, Volume: 77, Issue:4

    Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen

2020
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
    JAMA neurology, 2020, 04-01, Volume: 77, Issue:4

    Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen

2020
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
    JAMA neurology, 2020, 04-01, Volume: 77, Issue:4

    Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen

2020
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
    JAMA neurology, 2020, 04-01, Volume: 77, Issue:4

    Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen

2020
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
    JAMA neurology, 2020, 04-01, Volume: 77, Issue:4

    Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen

2020
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
    JAMA neurology, 2020, 04-01, Volume: 77, Issue:4

    Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen

2020
Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
    BMC neurology, 2019, Feb-09, Volume: 19, Issue:1

    Topics: Aged; Ambroxol; Brain; Dementia; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson D

2019
Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
    BMC neurology, 2019, Feb-09, Volume: 19, Issue:1

    Topics: Aged; Ambroxol; Brain; Dementia; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson D

2019
Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
    BMC neurology, 2019, Feb-09, Volume: 19, Issue:1

    Topics: Aged; Ambroxol; Brain; Dementia; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson D

2019
Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
    BMC neurology, 2019, Feb-09, Volume: 19, Issue:1

    Topics: Aged; Ambroxol; Brain; Dementia; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson D

2019

Other Studies

12 other studies available for ambroxol and Idiopathic Parkinson Disease

ArticleYear
Ambroxol reverses tau and α-synuclein accumulation in a cholinergic N370S GBA1 mutation model.
    Human molecular genetics, 2022, 07-21, Volume: 31, Issue:14

    Topics: alpha-Synuclein; Ambroxol; Cathepsin D; Cells, Cultured; Cholinergic Agents; Glucosylceramidase; Hum

2022
Generation of wild-type rat Glucocerebrosidase homology modeling: Identification of putative interactions site and mechanism for chaperone using combined in-silico and in-vitro studies.
    Bioorganic chemistry, 2022, Volume: 126

    Topics: Ambroxol; Animals; Catalytic Domain; Glucosylceramidase; Molecular Dynamics Simulation; Parkinson Di

2022
Precision Medicine for Parkinson's Disease: Ambroxol for Glucocerebrosidase-Associated Parkinson's Disease, First Trial Completed.
    Movement disorders : official journal of the Movement Disorder Society, 2020, Volume: 35, Issue:7

    Topics: Ambroxol; Glucosylceramidase; Humans; Mutation; Parkinson Disease; Precision Medicine

2020
Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data.
    American journal of hematology, 2021, 05-01, Volume: 96, Issue:5

    Topics: Adolescent; Adult; Aged; Ambroxol; Biological Availability; Blood-Brain Barrier; Child; Child, Presc

2021
Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism.
    Parkinsonism & related disorders, 2021, Volume: 84

    Topics: Adult; Aged; Aged, 80 and over; Ambroxol; Cells, Cultured; Enzyme Inhibitors; Female; Gaucher Diseas

2021
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
    Brain : a journal of neurology, 2014, Volume: 137, Issue:Pt 5

    Topics: Adult; Aged; Aged, 80 and over; Ambroxol; Cells, Cultured; Female; Fibroblasts; Gaucher Disease; Gen

2014
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
    Brain : a journal of neurology, 2014, Volume: 137, Issue:Pt 5

    Topics: Adult; Aged; Aged, 80 and over; Ambroxol; Cells, Cultured; Female; Fibroblasts; Gaucher Disease; Gen

2014
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
    Brain : a journal of neurology, 2014, Volume: 137, Issue:Pt 5

    Topics: Adult; Aged; Aged, 80 and over; Ambroxol; Cells, Cultured; Female; Fibroblasts; Gaucher Disease; Gen

2014
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
    Brain : a journal of neurology, 2014, Volume: 137, Issue:Pt 5

    Topics: Adult; Aged; Aged, 80 and over; Ambroxol; Cells, Cultured; Female; Fibroblasts; Gaucher Disease; Gen

2014
Magic shotgun for Parkinson's disease?
    Brain : a journal of neurology, 2014, Volume: 137, Issue:Pt 5

    Topics: alpha-Synuclein; Ambroxol; Female; Fibroblasts; Gaucher Disease; Glucosylceramidase; Humans; Male; M

2014
Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.
    Neurobiology of disease, 2015, Volume: 82

    Topics: Aged; Ambroxol; Antiparkinson Agents; Cells, Cultured; Female; Fibroblasts; Glucosylceramidase; Huma

2015
The contribution of mutant GBA to the development of Parkinson disease in Drosophila.
    Human molecular genetics, 2016, 07-01, Volume: 25, Issue:13

    Topics: Ambroxol; Animals; Disease Models, Animal; Dopaminergic Neurons; Drosophila melanogaster; Endoplasmi

2016
Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models.
    Scientific reports, 2016, 08-19, Volume: 6

    Topics: Ambroxol; Animals; Disease Models, Animal; Dopaminergic Neurons; Drosophila melanogaster; Endoplasmi

2016
Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice.
    Annals of neurology, 2016, Volume: 80, Issue:5

    Topics: alpha-Synuclein; Ambroxol; Animals; Brain; Disease Models, Animal; Expectorants; Gaucher Disease; Gl

2016
A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers.
    Stem cell reports, 2017, 03-14, Volume: 8, Issue:3

    Topics: Adipose Tissue; alpha-Synuclein; Ambroxol; Animals; Autophagy; Cell Differentiation; Dopaminergic Ne

2017